Compare BELFB & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BELFB | DYN |
|---|---|---|
| Founded | 1949 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | N/A | 2020 |
| Metric | BELFB | DYN |
|---|---|---|
| Price | $153.36 | $22.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 15 |
| Target Price | ★ $153.75 | $36.53 |
| AVG Volume (30 Days) | 186.0K | ★ 2.6M |
| Earning Date | 10-29-2025 | 11-05-2025 |
| Dividend Yield | ★ 0.18% | N/A |
| EPS Growth | ★ 19.52 | N/A |
| EPS | ★ 5.17 | N/A |
| Revenue | ★ $649,376,000.00 | N/A |
| Revenue This Year | $26.78 | N/A |
| Revenue Next Year | $6.19 | N/A |
| P/E Ratio | $29.84 | ★ N/A |
| Revenue Growth | ★ 23.70 | N/A |
| 52 Week Low | $58.00 | $6.36 |
| 52 Week High | $167.04 | $31.29 |
| Indicator | BELFB | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 53.49 | 61.55 |
| Support Level | $133.71 | $20.44 |
| Resistance Level | $152.26 | $22.27 |
| Average True Range (ATR) | 8.42 | 1.50 |
| MACD | 0.05 | -0.00 |
| Stochastic Oscillator | 56.56 | 98.32 |
Bel Fuse Inc designs and manufactures electronic components that protect and connect electronic circuits. Its product portfolio is divided into three categories: magnetic solutions, power solutions & protection, and connectivity solutions. These products are used for the computer, networking, telecommunications, transportation and defense/aerospace, automotive, medical, and consumer electronics industries. Its geographical segments are the United States, Macao, United Kingdom, Slovakia, Germany, Switzerland, and All other foreign countries. Majority of the revenue is derived from United States.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.